Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for DiabetesExclusive License Agreement • February 18th, 2020 • Genprex, Inc. • Pharmaceutical preparations
● Company licenses patented diabetes gene therapy technology designed by researchers at the University of Pittsburgh
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • February 18th, 2020 • Genprex, Inc. • Pharmaceutical preparations • Pennsylvania
This Exclusive License Agreement (“Agreement”) is made and entered into as of February 11, 2020 (“Effective Date”), by and between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 1st Floor Gardner Steel Conference Center, 130 Thackeray Avenue, Pittsburgh, Pennsylvania 15260 (“University”), and Genprex, Inc., a Delaware corporation, with its principal business at Dell Medical School, Health Discovery Building, 1601 Trinity Street, Suite 3.322, Austin, TX 78712 (“Licensee”).
